Probiotics have become a popular approach for managing digestive and immune health and are being recommended more frequently as effective therapeutic interventions by medical professionals. Introduced early in the 20th century, the science of probiotics has advanced considerably, especially in the past two decades. Researchers have adopted a consensus definition, begun to understand many of the mechanisms of action, defined characteristics important to probiotic function and have obtained clinical evidence supporting probiotic health benefits and product quality. Nonetheless, a need remains for clear, evidence-based communications to consumers on the role of probiotics in a healthy diet and to healthcare providers regarding clinical use. However, regulatory frameworks in many countries have restricted progress on this front. There is a need for additional research to further clarify the most effective probiotics for given health outcomes and to identify people most likely to respond to specific probiotic interventions. This review provides current perspective on the probiotic concept, discusses evidence-based probiotic interventions, considers fermented foods with regard to probiotics and addresses some regulatory challenges facing the probiotic field.
Probiotics in the 21st century
Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host (Hill et al. 2014) . This definition was issued by a consensus panel convened by the International Scientific Association of Probiotics and Prebiotics (ISAPP), which met to discuss the modern relevance of the 2001 Food and Agriculture Organization/World Health Organization definition of probiotics (FAO & WHO 2001) . In short, the panel reaffirmed all of the major principles of the 2001 definition.
'Probiotics' comprise many different types of microbes. It is important, therefore, to remember that they are described by their genus, species and strain designations. Using the example of one well-studied probiotic, Lactobacillus rhamnosus GG -Lactobacillus is the genus, rhamnosus is the species and GG is the strain designation. All three components are necessary to identify a probiotic. The full name enables the reader to link the specific strain to studies describing health benefits and safety assessments. Further, health benefits shown for one strain may not be established for another strain, even of the same species, although at times common mechanisms among different strains may result in similar clinical outcomes.
The ISAPP consensus panel addressed this evolving concept regarding the strain specificity of probiotic effects: that several probiotic mechanisms responsible for certain benefits may be commonly shared amongst most strains of a larger taxonomic group . For example, the production of organic acids, such as lactate and acetate, is shared by most species of both Bifidobacterium and Lactobacillus. These microbialproduced organic acids in the colon provide a range of potential benefits to the intestinal tract and beyond. They play an important role in creating a healthier gut environment by inhibiting undesirable microbes and by crossfeeding other beneficial gut microbes, resulting in production of butyrate, which fuels intestinal epithelial cells (Topping & Clifton 2001) . Thus, organic acids produced commonly by many different probiotic strains and species contribute to general gut health benefits (Ritchie & Romanuk 2012) . Identifying and establishing precise mechanisms responsible for any given health benefit remain active areas of research.
Despite the existence of shared, core mechanisms for probiotic functions, not all probiotic strains are the same. That is, while shared mechanisms exist, other mechanisms are likely narrowly distributed among probiotic species (Fig. 1) . Furthermore, strain specificity of probiotic benefits is the presumption unless mechanistic and clinical evidence suggests otherwise.
In the global marketplace, probiotics are found primarily in three main categories -foods, dietary supplements and pharmaceuticals. The regulatory category of some newer products containing probiotics is unclear. For example, probiotic cosmetics are now being offered. Many regulatory frameworks strictly control the level of live microbes in cosmetic products for safety reasons; yet to be considered a 'probiotic' such products must deliver effective doses of live microbes. Another question is if cosmetic benefits, such as teeth whitening, can be considered a 'health benefit', as stipulated by the probiotic definition. Products such as probiotic lozenges, throat sprays and chewing gum do not fit neatly into a food or supplement category. Further, humans are not the exclusive target for probiotics, as probiotics for pet and animal husbandry applications are available.
The quality of probiotic products, including reliability and accuracy of product labelling, can vary considerably amongst the product category and geographical regions. Currently, there is no global harmonisation of regulatory frameworks dictating manufacturing and claim substantiation requirements for probiotics. Consumers and manufacturers would greatly benefit from efforts to verify product quality through a third party. This is the goal, for example, of the US Pharmacopeia (Rockville Maryland, US), which has assembled a panel of probiotic experts to provide advice and recommendations on quality issues including identification, enumeration and standards for contaminating microbes as applicable to probiotic dietary supplements.
The microbes most commonly used as probiotics include species from the genera Lactobacillus, Bifidobacterium and Saccharomyces. Probiotics from other genera include Bacillus, Propionibacterium, Streptococcus and Escherichia. There is active research on identifying novel candidate probiotic species isolated from different sites of healthy human subjects. These 'next generation' probiotics are likely to be developed as pharmaceutical products (O'Toole et al. 2017) .
Robust clinical investigations into the health benefits of probiotics have been underway since the 1990s and many of these human trials have documented a diverse array of benefits (see 'Health benefits of probiotics: Evidence for specific effects' section). The probiotic field has benefited from advances in human microbiome research, which have shown that the microbiota colonising healthy humans often differ from the microbiota of humans with certain diseases or health conditions. Colonising microbes have been shown to respond to diet, including diets containing live microbes as part of fermented foods, and nutritional status is affected by the function of the gut microbial community (David et al. 2014) . Probiotics are poised as a valuable means of influencing the function of the gut ecosystem to improve nutritional status and health (Versalovic 2013 ).
Characteristics of probiotics
Although there are many characteristics of probiotic microbes, it is useful to remember what the ISAPP consensus probiotic definition stipulates: a probiotic must be alive when administered, have a health benefit and be delivered at an effective dose (Hill et al. 2014) . According to the ISAPP consensus panel (Hill et al. 2014) , the definition implies that a probiotic must be safe for the intended use and must be a defined entity (not an undefined mixture) to allow for appropriate identification to the strain level. There is no requirement for probiotics to exhibit properties in pre-clinical assessments such as colonisation, ability to survive intestinal transit, adherence, anti-pathogenic properties and ability to balance the host microbiota. Further, the source of the probiotic strain -human or otherwise -is not stipulated in the definition. These attributes may be useful for probiotics intended for particular applications but there may be no need, for example, for a probiotic used for oral health to be able to survive intestinal transit. Further, although many probiotic researchers both historically and in recent years utilised a battery of such tests to describe putative probiotics, these tests have never been validated (Flach et al. 2017) and the outcomes of these tests have never been linked to probiotic efficacy. Thus, making such tests a 'requirement' for probiotic status is not scientifically justified.
Probiotics may have far-reaching benefits. This is possible due to the variety of probiotic activities that may evoke a physiological benefit. But as mentioned earlier, probiotics are not one substance, and as biological entities, they have the potential to act in diverse ways. Mechanisms of action that researchers have discovered in different probiotic strains include modulation of immune system, interactions with gut microbiota, production of organic acids, competitive exclusion, improved barrier function, manufacture of small molecules with systemic effects and production of enzymes (O'Toole & Cooney 2008) . Many gaps in the existing knowledge of the mechanisms underpinning health benefits remain, however. Not all mechanisms have been demonstrated in humans and, more importantly, in many cases, conclusive evidence that a given mechanism is related to a specific health outcome in humans is lacking. Further, as biological entities, probiotics are likely to express more than one mechanism that may contribute to a given clinical outcome, complicating research efforts to identify mechanisms of probiotic function in humans.
One purported probiotic effect that has been difficult to establish in healthy humans is modification of the composition of the gut microbiota. Although a common view is that probiotics 'promote a healthy microbiota composition', there is little evidence that probiotics have a substantive impact on the overall structure of gut microbial communities of healthy subjects beyond the transient increase in the specific strain being consumed (Kristensen et al. 2016) and probiotic microbes rarely persist for more than a couple of weeks after consumption (Sanders 2011) . A systematic review of studies of the impact of probiotics on faecal microbiota found no effect on a range of microbiota composition measures (alpha-diversity, richness or evenness) (Kristensen et al. 2016) . Despite the transient nature of probiotics and the absence of dramatic changes in the microbiota during probiotic consumption, health benefits are substantiated by clinical evidence (See 'Health benefits of probiotics: Evidence for specific effects' section). These observations suggest that beneficial effects of probiotics arise without the need for colonisation of the gastrointestinal tract or a subsequent alteration of faecal microbiota composition.
Fermented foods: Another source of probiotics?
Fermented foods and beverages have a long and important cultural and culinary history (Marco et al. 2017) . Fermented milk, meat and plant-based foods have been dietary staples for thousands of years (Hutkins 2006) . Several properties likely contributed to the popularity of these products. Fermented foods are well-preserved and would have provided a stable food source when fresh foods were scarce. Fermented foods and beverages also have unique sensory properties that would have appealed to consumers. Enhanced functionality -for example, converting simple cereal grains into bread or beer -would have also led to widespread appreciation of fermented foods.
In the past century, and especially the past decade, the nutritional benefits of fermented foods have been recognised. These foods are usually made from nutrient-dense starting materials such as milk, meat, grains and legumes that are already good sources of protein, vitamins and minerals. However, fermented foods may possess benefits beyond these major nutrients. In particular, emerging evidence suggests that the live microorganisms present in fermented foods contribute to both gastrointestinal and systemic health (reviewed in Marco et al. 2017) .
In general, most fermented foods contain microorganisms that were either (i) added as a culture to initiate the fermentation or (ii) already present in the starting material and enriched during fermentation. Virtually all the cheeses and yogurts consumed in the US are made by the former method (i.e. using specially selected strains of lactic acid bacteria). In contrast, the manufacture of other fermented foods -for example, sauerkraut and kimchi -relies on indigenous or wild microorganisms.
In addition, it is now a common practice to add specific probiotic microorganisms to fermented foods. Thus, many of the commercial yogurt and cultured milk products now contain probiotic strains of Lactobacillus and Bifidobacterium. In these applications, the fermented food becomes the delivery vehicle for the probiotic.
The distinction between probiotic microorganisms and fermentation-associated microbes is important but often confused. As noted above, probiotics refer to those live microorganisms that confer a health benefit on the host. To document a health benefit, human trials must be conducted. Such clinical evidence is obtained using a well-defined intervention, in this case, microbial strains. However, the live microorganisms that are responsible for spontaneous food fermentations are rarely suitably defined. Moreover, the specific microorganisms in kimchi, sauerkraut, miso and other spontaneous food fermentations will be different from batch-to-batch as well as between manufacturer and location. Thus, unless the relevant strains were isolated from each fermentation, it would be virtually impossible to assess their potential probiotic properties. Therefore, not all fermented foods are probiotic foods, as undefined and unstudied products do not meet the minimum criteria of a probiotic.
However, to the extent a probiotic is added to a fermented food, or included in the production of a fermented food, then that fermented food would also be a probiotic food. Indeed, the European Food Safety Authority (EFSA Panel on Dietetic Products 2010) has approved a health claim for yogurt, having determined that the yogurt bacteria (Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus) at the species level can help improve digestion of lactose among individuals with lactose maldigestion.
The beneficial health effects of yogurt and other fermented foods are supported by several epidemiological studies. For example, reduced risk of metabolic syndrome was associated with yogurt-rich diets in one large cohort study of older adults (Babio et al. 2015) . Similarly, in another large cohort study, yogurt consumption was associated with less long-term weight gain (Mozaffarian et al. 2011) . The results of the Malm€ o diet and cancer cohort study showed that consumption of fermented dairy products (mainly yogurt and sour milk) was inversely associated with risk of cardiovascular disease (Sonestedt et al. 2011) . Cheese consumption showed a similar effect, but only in women. Two large cross-sectional analyses of adults in Korea showed that high consumption (2-4 servings per day) of kimchi and other fermented foods and beverages was associated with reduced prevalence of atopic dermatitis (Park & Bae 2016; Kim et al. 2017) . Consumption of miso, natto and fermented soy products was also inversely associated with reduced risk of high blood pressure (Nozue et al. 2017) . In contrast, in another large cohort study, consumption of fermented foods (mainly dairy) was not associated with reduced mortality to all causes, cancer or cardiovascular disease (Praagman et al. 2015) . The exception was for cheese consumption, which, in this study, as also observed previously (Sonestedt et al. 2011) , was inversely associated with cardiovascular disease mortality. Although these epidemiological studies generally distinguish between the type of fermented foods consumed by cohort participants, consumption of unsaturated and saturated fat, fibre and other dietary components may ultimately influence outcomes. Other potential confounders include exercise, stress and lifestyle.
Fewer studies have directly assessed the role of fermented foods on clinical health outcomes. Although microbes originating from fermented foods are detected in faecal samples (Dal Bello et al. 2003; David et al. 2014; Zhang et al. 2016a) , these microorganisms are transients and do not colonise or persist. Still, even if fermentation-associated microbes are just passing through, there is emerging evidence that they can nonetheless influence the normal microbiota, communicate with the host immune system and exert other positive effects (reviewed in Marco et al. 2017) . Outcomes of recent clinical trials include improvements in blood pressure in hypertensive adults by fermented milk (Beltran-Barrientos et al. 2018), reduction of infectious disease among children by fermented rice or milk (Nocerino et al. 2017 ) and short-term improvements in bone health markers in osteoporosis patients by kefir (Tu et al. 2015) .
In addition to the health effects of ingested microbes, there are other ways fermented foods can contribute to improved health. First, microorganisms can transform or change the chemical content of a food during the fermentation and thereby alter the nutritional properties. Examples would include the utilisation of lactose during cheese manufacture and the partial degradation of gluten during sourdough fermentation. Similarly, in rye and other wholegrain sourdoughs, low pH enhances the hydrolysis of the anti-nutrient, phytic acid, by endogenous amylases, and increases the nutritional value of the bread (Ganzle 2014) . During the manufacture of red wine, ethanol produced during the maceration step enhances extraction of phenolic compounds known for their biological activity (De Beer et al. 2002; Setford et al. 2017) . Finally, fermentation microbes may increase the vitamin content of foods, as occurs in cultured dairy products and other fermented foods (LeBlanc et al. 2011; Chamlagain et al. 2018) .
Health benefits of probiotics: Evidence for specific effects
This section focuses on clinically relevant endpoints from human studies that are associated with probiotic use. Evidence must be viewed as being applicable to the specific probiotics and doses tested; not all strains of probiotics will be functional for all the endpoints listed. Table 1 summarises the range of benefits that have been tested in randomised controlled trials (RCT) for some probiotics. As with all intervention substances, including drugs, supplements and foods, there are null trials in probiotics. Null trials provide important lessons to better understand the limitations of certain probiotic interventions and indications. However, it is important to consider these results in the context of the totality of evidence.
Many researchers have considered the totality of evidence for probiotics on a given endpoint by conducting a systematic review that includes studies on different strains. However, not all probiotic strains can be expected to be equally effective clinically. To the extent that common mechanisms among different strains drive the observed clinical benefits, it is scientifically sound to consider evidence on similar but not identical interventions (Glanville et al. 2015) , as is often done for drugs as can be seen in this meta-analysis of all antibiotics for chronic obstructive pulmonary disease (COPD) exacerbations (Lyon et al. 2018 ).
Infantile colic
Colic in an otherwise healthy child is defined as inconsolable crying for more than 3 hours per day, more than 3 days per week, for longer than 3 weeks (Johnson et al. 2015) . This is a common condition and is very difficult to treat. No traditional medical intervention is effective for colic (Johnson et al. 2015) . Although colic occurs in up to 20% of infants, the aetiology remains unclear (Sung et al. 2014) . Diet and intestinal microbiome likely play a role, with lower counts of lactobacilli being reported in the intestinal microbiota of colicky infants (Savino et al. 2004 (Savino et al. , 2005 . These early studies motivated researchers to study the effect of probiotics on colic. One microorganism, L. reuteri 17938, is the most widely studied strain as an intervention given to infants suffering from colic. In an individual participant data metaanalysis (Riley et al. 2010) (considered the highest level of evidence), four double-blind trials involving 345 infants with colic (174 probiotic, 171 placebo) receiving L. reuteri 17 938 or placebo were analysed. L. reuteri 17 938 treatment statistically significantly decreased daily crying time [À25.4 minutes (95% CI: À47.3, À3.5)], and a 28% success rate in the probiotic group versus 9% in placebo group was demonstrated. This translates into a number needed to treat (NNT) of 4. Importantly, no adverse events were attributed to L. reuteri 17938 treatment (Sung et al. 2018) . This effect was only demonstrated in breastfed infants.
Eczema
Atopic eczema is an inflammatory skin condition characterised by pruritus, redness and thick and scaly skin (Berke et al. 2012) . It is often associated with other atopic diseases such as allergic rhinitis and asthma; an estimated 30% of children with atopic dermatitis develop asthma later in life (Spergel 2010) . A metaanalysis of 29 studies found probiotics reduced the risk of developing eczema in infants when consumed by women during the last trimester of pregnancy [relative risk (RR) = 0.71; 95% CI: 0.60-0.84], when used by breastfeeding mothers (RR = 0.57; 95% CI: 0.47-0.69) or when given to infants (RR = 0.80; 95% CI: 0.68-0.94) . These findings resulted in the World Allergy Organization (WAO) convening a guideline panel to develop evidence-based recommendations about the use of probiotics in the prevention of allergy . The WAO panel recommended: (1) using probiotics in pregnant women at high risk for having an allergic child; (2) using probiotics in women who breastfeed infants at high risk of developing allergy; and (3) using probiotics in infants at high risk of developing allergy. Both the WAO and the meta-analysis review acknowledge that more studies need to be conducted because existing data, although promising and positive, constitute a low evidence level due to a high risk of bias, inconsistency and imprecision of results. However, when considering the potential benefit and negligible risk, the limited data were sufficiently convincing for a recommendation to be made.
Inflammatory bowel diseases
There is high incidence of inflammatory bowel diseases (IBD) [ulcerative colitis (UC) and Crohn's disease] in Western countries, with diet, genetics and environment appearing to affect prevalence (Friedman & Blumberg 2014) . Additionally, antibiotic treatment in the first year of life appears to confer an almost three times greater risk of developing IBD (Friedman & Blumberg 2014) . Because of the apparent association of diet and microbiome with IBD, there is considerable interest in dietary interventions and/or probiotic supplementation as a treatment. Interestingly, many of the same traditional medicines are used for both UC and Crohn's disease, but trials testing probiotics as a treatment for Crohn's disease have consistently failed, suggesting that at least the probiotics tested to date are an ineffective treatment for Crohn's disease, as was observed in the trial by Bourreille et al. (2013) . There have been a few positive studies with different products/strains in patients with UC, primarily with VSL#3 and E. coli Nissle 1917 (Floch et al. 2015) . A meta-analysis of 319 UC patients taking VSL#3 or matching placebo found the remission rate in the VSL#3 patients was 44.6% vs. 25.1% in placebo, NNT = 4 (Cordina et al. 2011; Mardini & Grigorian 2014) . VSL#3 has now been added to the formulary of some UK hospitals and is prescribed by some gastroenterologists as an adjunctive treatment for UC, although this is not standard practice in the UK.
Antibiotic-associated diarrhoea and Clostridium difficile infection
Antibiotics are amongst the most commonly prescribed drugs in UK hospitals. However, as well as treating infection they can cause disruption to the gastrointestinal microbiota. This can lead to the relatively common side effect of antibiotic-associated diarrhoea (AAD), which often delays hospital discharge. More concerning is that a disruption to the normal gut microbiota can lead to reduced resistance to opportunistic pathogens such as Clostridium difficile, leading to C. difficile infection (Schaffler & Breitruck 2018 ), a potentially severe or fatal infection causing over 30 deaths a year in the UK (PHE 2018; ONS 2017) . Several studies have shown that probiotics taken with antibiotics reduce the incidence of C. difficile-associated diarrhoea (CDAD) and AAD. Administration of Saccharomyces boulardii, a probiotic yeast, compared with placebo or no treatment, reduced the overall risk of AAD in patients treated with antibiotics from 18.7% to 8.5% (NNT = 10) (Szajewska & Kolodziej 2015) . A recent meta-analysis of 7957 patients (Lau & Chamberlain 2016) and the latest Cochrane meta-analysis of 9955 patients (Goldenberg et al. 2017) showed~60% reduction of risk of developing CDAD when patients were co-prescribed probiotics with antibiotics, along with a decrease in the risk of developing side effects related to antibiotics (Goldenberg et al. 2017) . There is still much to be learnt about the optimum timing, duration, formulation and dosing of probiotic supplementation for reducing risk of CDAD. This is illustrated by the null result from a large multi-centre, placebo-controlled trial testing a probiotic to prevent C. difficile diarrhoea in older inpatients [the PLACIDE study (Allen et al. 2013) ]. This study may have failed to show a benefit from probiotics due to the low incidence of AAD and CDAD (10% actual compared to 20% predicted), the mismatch between period of probiotic administration (21 days) and diarrhoea incidence tracking (8 weeks) and the long period allowed between antibiotic administration and commencement of probiotic intervention (7 days). It is, however, reassuring that this study administered probiotics to nearly 1500 patients over 65 years of age had no adverse effects attributable to the intervention (Allen et al. 2013) . Several hospitals across the UK have implemented co-prescribing of a probiotic with antibiotic therapy, especially in at-risk populations, but this has not yet become standard practice.
Necrotising enterocolitis
Necrotising enterocolitis (NEC) is a serious neonatal disease causing inflammation and necrosis of areas of the bowel, primarily in premature infants and those with a birthweight of <1500 g. It carries a significant mortality of up to 30% (Gephart et al. 2012) . Although the aetiology is incompletely understood, it is thought to relate to aberrant intestinal mucosal colonisation by bacteria. Research efforts have focused on therapeutics designed to restore this balance to prevent NEC or minimise the severity once it has occurred (Denning et al. 2017; Eaton et al. 2017; Frost et al. 2017) . In 2014, a Cochrane review found that the use of probiotics reduced the occurrence of NEC (typical RR 0.35; 95% CI: 0.24 to 0.52, NNT 25) and death (typical RR 0.40; 95% CI 0.27 to 0.60, NNT 25) in premature infants with a birthweight of <1500 g (AlFaleh & Anabrees 2014). The routine use of probiotics in neonates has been incorporated into clinical guidelines in multiple UK hospital trusts and is recommended by the South West Neonatal Network (Bartle et al. 2016) . However, although several RCTs have shown that probiotics can reduce neonatal morbidity and mortality, these studies used several different probiotic strains, and no comparative trials have been conducted to determine the most effective probiotics. Indeed, the largest UK multi-centre RCT studying 1315 premature infants showed no effect of the probiotic B. breve BBG-001 on either the occurrence of NEC or associated mortality, although importantly there were no probiotic-related adverse effects (Costeloe et al. 2016) . A recent network meta-analysis including data from 11 231 preterm infants identified that only three of 25 probiotic formulations were efficacious in reducing mortality from NEC, whereas seven strains were effective in reducing incidence of NEC and there was no clear overlap between these formulations (van den Akker et al. 2018) . These data highlight the importance of the choice of probiotic formulation and that further high-quality studies are required for optimal strain and dose selection. It is evident that selecting a probiotic without consideration as to the optimal dose, strain, combination and formulation can lead to clinical inefficacy, and this is an important consideration moving forwards. However, when the optimal probiotic intervention is applied to the right patient population, the results can be promising. A recent large-scale clinical trial conducted in 4556 healthy infants in rural India showed a significant reduction in neonatal sepsis with a synbiotic formulation of L. plantarum ATCC-202195 and fructooligosaccharide (RR = 0.60; 95% CI: 0.48-0.74, NNT = 27) (Panigrahi et al. 2017) . Neonatal sepsis remains a significant cause of death, particularly in the developing world, and with the increasing global concerns about antibiotic resistance probiotics may offer an attractive option for prevention or adjunctive treatment of infection.
Do probiotics have any benefit for generally healthy people?
Probiotic intervention studies have been conducted on healthy or 'at-risk' subjects targeting diverse clinical endpoints. Taken together, these studies suggest that there may be some benefit in free-living, generally healthy people. For example, studies have shown that probiotics can modestly decrease the incidence (Hao et al. 2015) and duration (King et al. 2014) of common upper respiratory tract infections in children. Some evidence exists for certain probiotics to help manage blood lipids in people with mild hypercholesterolemia (Wang et al. 2018) . Probiotics can improve lactose digestion in lactose intolerant people, with most evidence showing that lactose consumed in yogurt with live cultures is better tolerated than the same amount of lactose consumed without live cultures (Oak & Jha 2018) . A recent systematic review evaluated the role of probiotics in the management of lower gastrointestinal symptoms (Hungin et al. 2018) . Included studies covered a range of symptoms experienced by healthy subjects or subjects with minor gastrointestinal symptoms. Consensus statements were considered by a panel of 14 experts on behalf of the European Society for Primary Care Gastroenterology. In short, the panel agreed that specific probiotics should be tried or considered for management of several symptoms of IBS, although not all probiotics showed benefit. Observed benefits for IBS may be of modest magnitude, strain-specific and depend on the host physiology, diet and colonising microbiota.
Suggestions to help understand the marketplace
The probiotic marketplace can be confusing for consumers. Box 1 answers some frequently asked questions consumers commonly pose. The overriding need is for consumers to be able to recognise products of high quality that address their specific needs. Probiotic quality encompasses safety, potency and correctness of product labelling, including the accuracy of any health benefit claims, to the extent claims are allowed.
The safety of any probiotic must be definitively established for the intended use. Although probiotics that are commonly marketed have an excellent safety record (Sanders et al. 2010; Hempel et al. 2011) , additional concerns may exist for probiotics intended for vulnerable patient populations (Sanders et al. 2016) . Good manufacturing practices for any product category must be met, but since probiotics are live microorganisms, special approaches may be needed for verification that no undesirable microbes contaminate the product.
A probiotic product label (Fig. 2) should disclose the genus, species and strain designation for all strains in the product (FAO & WHO 2002) . How microbes are classified and named (the field of nomenclature) can change based on the latest science, and consumers are best served when manufacturers use accurate and the most current names. Without this information, it is impossible for experts, healthcare providers or consumers to verify that scientific substantiation exists for the product as formulated.
Product labels should also contain information on the potency of the product. This is typically expressed as 'colony forming units' (CFU), a unit based on culturing and counting the number of live microbes able to form a colony on an agar plate. An emerging technique, flow cytometry, improves precision and throughput of probiotic enumeration, and in the future active fluorescent units may replace CFU on product labels (Chiron et al. 2018) . The CFU per serving or dose of a probiotic should be that which can be guaranteed through the end of shelf life and matches the dose used in human studies demonstrating a health benefit.
Perhaps the most contentious aspect of probiotic product labelling is for health benefit claims. Different region's regulatory frameworks impose different standards of evidence to support claims. Further, some regions require pre-approval of claims whereas others do not. In the European Union (EU), all claims must be approved by regulatory authorities and probiotic claims submitted to date have not been approved. The dossiers submitted in support of the claims have been deemed to not establish a cause-and-effect relationship between a probiotic product and the claimed health effect. The applied standard in the EU is the 'highest possible standard' of evidence and all studies must be conducted on healthy subjects to be considered. In the US, the situation is different.
Structure/function claims (claims that relate the substance to the normal structure or function of the healthy human body) do not require approval, whereas claims that relate the food to the reduction of risk of disease must be approved . There are suggestions in a guidance document (which are not legally binding) that that the US Food and Drug Administration (FDA) deems health benefit
Box 1: Frequently asked questions about probiotics
See ISAPP for additional information in the form of infographics (https://isappscience.org/infographics/) or short videos (https://isappscience.org/resources/isapp-videos/). Q. Is a higher dose and greater number of strains better? A. Not necessarily. The recommendation is to use products that have been tested in human studies with positive outcomes for the benefit you are interested in. Sometimes the probiotic product shown to be effective might have a lower dose or fewer strains than another product.
Q. Does the sugar in probiotic yogurts negate the benefits of probiotic yogurt? A. Most studies testing the health benefits of yogurt have been conducted on sweetened yogurts. Therefore, the sugar present in these products does not negate the probiotic effects. However, sweetened yogurts should be consumed only in the context of a healthy, balanced diet.
Q. Are refrigerated products better than non-refrigerated? A. The stability of the live microbes in a probiotic product depends on conditions of storage. Some products may require refrigeration, but others do not. Responsible product manufacturers make certain that their probiotic is able to meet its label claim through the end of shelf-life if stored as recommended.
Q. Is it better to take probiotics as supplements or foods? A. Human trials have shown benefits for both food and supplement forms of probiotics, and no comparative trials have been conducted suggesting one format is better than the other. If multiple products of different formats have been shown to be effective, then take the product that best fits with your diet and lifestyle.
Q. What is the difference between probiotics and prebiotics? A. Probiotics are live microorganisms beneficial to your health. Prebiotics are not live microbes, but are substances that are used by your beneficial, colonising microorganisms. Simply put, prebiotics are food for your beneficial, native bacteria. Most prebiotics are a type of fibre.
Q. The body already has so many bacteria, how can we expect the comparatively small number of live microbes in a probiotic product to have any benefits? A. Our bodies are home to trillions of microbes. But remember that we are not uniformly colonised, even throughout the digestive tract. Orally consumed probiotics travel through some sparsely colonised regions of the upper digestive tract, and may be dominant during this passage. Further, even as minor components of the lower digestive tract, a probiotic's metabolic activities can impact the gut environment. Some probiotics have been shown to influence some clinical outcomes, and that's what is important. claims for food should be restricted to taste, aroma and nutritive value, which would greatly limit the scope of functional claims for foods (US Food and Drug Administration 2016). In practice, functional claims on foods have not complied with this guidance. In the US, there are no approved probiotic drugs, and any product making an unapproved drug claim (that the product can cure, treat, prevent or mitigate disease) will receive a cease-and-desist warning letter from the FDA. Any manufacturer interested in making such claims needs to go through the drug approval process, and to date, none have.
As delineated in the 'Health benefits of probiotics: Evidence for specific benefits effects' section, there is compelling evidence that probiotics may benefit human health in several ways. Whereas scientific publications including systematic reviews and metaanalyses that consider the totality of the evidence will communicate these benefits, currently, due to limitations of different regulatory frameworks, often product labels and advertising cannot. Healthcare providers interested in evidence-based probiotic usage often do so using an 'off-label use' strategy. Consumers interested in using probiotic products to alleviate a particular health concern can find it difficult to identify products that have been tested for such benefits. Some guidelines that provide evidence-based recommendations for probiotic use include the World Gastroenterology Organisation Practice GuidelineProbiotics and Prebiotics (Guarner et al. 2017) , Clinical Guide to Probiotic Products Available in the US (Skokovic-Sunjic 2018; funded by probiotic companies, but independently conducted reviews) and European Society for Paediatric Gastroenterology, Hepatology and Nutrition (Braegger et al. 2011; Szajewska et al. 2014 Szajewska et al. , 2016 Kolacek et al. 2017) .
Conclusions
The probiotic concept, first introduced in the early 1900s, has been updated by ISAPP to include current evidence levels. Research suggests that probiotics can be used in an evidence-based manner to address a range of different health concerns. For the healthy consumer, probiotics and fermented foods may provide a dietary approach to support health and better function of the gut microbiota. Many other potential health benefits for probiotics (not discussed in this review) are currently under investigation, including their role in reducing the perception of stress, anxiety, depression and other expressions of brain function (Sarkar et al. 2016) . The possible roles of probiotics in reducing diseases associated with faulty immune programming leading to autoimmune disorders or correcting dysbiosis that might influence metabolic disorders are also being studied. Research is needed to determine if current or future, so-called next generation, probiotics can help address these disorders. Although current probiotic products are most commonly available in food and supplement formats, it is likely that in the near future these next generation probiotics will be available as drugs targeted towards specific diseases (O'Toole et al. 2017) . Regulatory challenges for communication of findings from efficacy research remain. As the impact of probiotic interventions on the gut microbiota are further investigated, it may soon be possible to identify likely responders to a specific probiotic, enabling more successful utilisation in the future. 
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